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Abstract We determined whether persistent nausea and
vomiting (N/V) symptoms following Roux-en-Y gastric
bypass surgery is due to elevated systemic glucagon-like
peptide-1 (GLP-1) and leptin in female non-diabetic sub-
jects. Subjects with N/V post-Roux-en-Y gastric bypass
(RYGB) surgery had significantly elevated fasting GLP-1
levels compared to that with post-operative asymptomatic
subjects and to morbidly obese, obese and lean subjects
not undergoing surgery. Weight loss, glycaemia, insulin
and post-prandial GLP-1 levels were similar in all post-
operative subjects. Despite comparable BMI, leptin was
significantly lower in symptomatic subjects. Furthermore,
leptin secretion from subcutaneous adipose tissue was
inhibited by GLP-1 (0.1–1.0 nM; n=6). Persistent N/V
following RYGB surgery is associated with elevated
fasting GLP-1, but lower leptin levels. The latter may
be a consequence of the direct GLP-1 inhibition of leptin
secretion from adipose tissue.
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Introduction
Bariatric surgery is to date the only intervention that results in
significant and sustained weight loss for morbid obesity [1].
Procedures such as Roux-en-Y gastric bypass (RYGB), which
combines gastric restriction with the bypass of the stomach
and proximal intestine, are more effective than other forms of
metabolic surgery [1]. However, a proportion of patients
develops sustained and debilitating nausea and vomiting
(N/V) symptoms after RYGB as well as with other procedures
such as sleeve gastrectomy that is not related to mechanical
obstruction [2, 3].
Glucagon-like peptide-1 (GLP-1) is an incretin hormone
synthesised and secreted by endocrine L cells in the small
intestine and centrally by neurons in the nucleus tractus
solitarius (NTS) of the brainstem. Under physiological condi-
tions GLP-1 augments insulin secretion after nutrient inges-
tion and decelerates gastric emptying and inhibits intestinal
transit time [4]. GLP-1 infusions reduce energy intake in lean
and overweight subjects [4]. Endogenous GLP-1 appears to
reduce food intake by acting in a paracrine-like fashion on
adjacent GLP-1 receptors (GLP-1R) expressed on vagal affer-
ents innervating the GI tract, rather than acting directly on
GLP-1R in the brain [4].
A recognised side effect of GLP-1 analogues used to treat
diabetes is nausea, which occurs in up to 50 % of patients [5].
Studies in rats suggest that the nausea-inducing effects of
peripheral exendin-4, a GLP-1R agonist, are mediated by a
vagal-independent pathway that appears to involve the blood
brain barrier (BBB) penetrance and subsequent GLP-1R acti-
vation in the central nervous system (CNS), most likely in the
NTS [6]. Post-prandial GLP-1 plasma levels are significantly
increased following RYGB and remain elevated for at least
1 year [7]. Increased GLP-1 levels are associated with en-
hanced satiety and are hypothesised to be related to decreased
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gastrointestinal transit time in bypass patients rather than
weight loss alone [8].
There is also data suggesting a relationship between leptin
and symptoms of severe, but not mild-moderate, nausea in
women during pregnancy [9, 10]. Furthermore, the most
common side effect of treatment with metreleptin is nausea
[11]. Thus, whether leptin may provoke N/V in a subset of
women following RYGB has not been investigated. The aim
of this study was to test whether increased GLP-1 and leptin
levels after surgery could be a contributing factor to the
persistent N/V. We compared post-absorptive and post-
prandial levels of GLP-1 and leptin between asymptomatic
subjects and patients with persistent N/V following RYGB
and between lean, overweight and obese subjects not sched-
uled for surgery. In addition, we determined the possibility of
cross-talk between the gut peptide and adipokines, by inves-
tigating the effect of GLP-1 on leptin secretion in vitro.
Subjects and Methods
Subjects
Five groups of subjects were recruited; obese subjects with
persistent and prolonged N/V after RYGB (group 1: n=10),
asymptomatic post-operative obese subjects (group 2: n=10),
morbidly obese subjects (group 3: n=7), overweight/obese
subjects (group 4: n=6) and lean healthy subjects (group 5:
n=9). Subjects in group 1 had upper gastrointestinal tract
endoscopy and imaging to exclude an obstructive cause for
their symptoms. The subject characteristics are shown in
Table 1. Exclusion criteria were current treatment with warfa-
rin or non-steroidal anti-inflammatory drugs (NSAIDs), type 2
diabetesmellitus (T2DM) andmalignancy or substance abuse.
The study was approved by the National Research Ethics
Committee, and written informed consent was obtained from
all participants.
Subjects attended the hospital outpatient clinic in the
morning after an overnight fast. The post-operative pa-
tients were studied 18.8±3.0 months after surgery.
Fasting blood samples were collected for measurement
of plasma glucose, lipids, insulin, leptin, adiponectin and
GLP-1. Subjects consumed a standard 180 kcal meal
(9.6 g of fat, 44.3 g of carbohydrate and 8.5 g of
protein), and additional blood samples for GLP-1, glu-
cose and insulin were collected at 45, 120 and 180 min
after the meal. The meal size was determined by subjects
with post-operative N/V unable to tolerate larger
portions.
Anthropometric Measurements
BMI was calculated as the weight (kg) divided by the square
of the height (m2). Blood pressure was measured with a digital
device (Omron, Netherlands).
Assays
Plasma glucose, serum triglycerides, total, low-density lipo-
protein (LDL) and high-density lipoprotein (HDL) cholesterol
















Age (years) 41.4±3.4 38±3.1 39.3±4.3 45.5±3.9 34.7±4.6
BMI (kg/m2) 30.6±2.3 31.2±2.0 46.3±1.7 31.8±1.9 21.3±0.7
SBP (mmHg) 119±3 109±3 127±7 121±12 21.3±1
DBP (mmHg) 73±5 72±3 81±4 79±2 76.6±12
Fasting glucose (mmol/l) 5.0±2.4 4.5±0.5 5.07±0.9 5.2±0.7 4.7±0.5
Fasting insulin (mIU/l) 5.0±2.4 4.5±1.5 10.2±7.5 9.4±4.1 4.1±2
HOMA-IR 1.2±0.6 0.9±0.3 2.4±2.2* 2.1±0.8* 0.8±0.4
Total cholesterol (mmol/l) 3.5±0.35 4.1±0.12 4.0±0.43 4.4±0.26 4.9±0.38
HDL cholesterol (mmol/l) 1.2±0.12 1.4±0.12 0.99±0.07 1.3±0.14 1.9±0.29**
LDL cholesterol (mmol/l) 1.8±0.29 2.4±0.25 2.5±0.41 2.7±0.23 2.6±0.29
Triglycerides (mmol/l) 1.1±0.23 0.85±0.05 1.1±0.18 0.81±0.24 0.81±0.13
Data are expressed as mean±standard deviation
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HOMA-IR homeostatic model assessment-insulin resistance, HDL
high-density lipoprotein, LDL low-density lipoprotein. N/V nausea and vomiting, MO morbidly obese, OW obese and overweight
*p<0.05 compared to the post-surgery and lean groups; **p<0.05 comparing the lean to all other groups
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concentrations were determined with commercial reagents.
Glucose and lipid assays were performed in the pathology
laboratories at the Whittington Hospital using routine proce-
dures. GLP-1 levels were measured by ELISA specific for the
active form of GLP-1 (7–36). Leptin, adiponectin and insulin
levels were determined using commercially available ELISA.
Insulin resistance (IR) was calculated by the homeostatic
model assessment (HOMA) using: HOMA-IR=(glucose in
mmol/l×insulin in mIU/l)/22.5.
In Vitro Study
Abdominal subcutaneous adipose tissue (SAT) samples were
obtained from six morbidly obese, non-diabetic patients un-
dergoing bariatric surgery (mean age 47.6±9.9 years, BMI
43.6±8.0 kg/m2) for use in organ cultures. SATorgan cultures
(0.05 mg/500 μl) were incubated in serum-free media with
1 % penicillin/streptomycin solution containing recombinant




Fig. 1 a Weight loss following Roux-en-Y gastric bypass in subjects
with and without persistent nausea and vomiting symptoms. BMI of
patients with and without persistent N/V symptoms was recorded for
15 months following RYGB (n=10 per group). There were no significant
differences in the change in BMI over time between the two groups. Data
are shown asmean and standard deviation and comparisons carried out by
t test.N/V nausea and vomiting, BMI bodymass index, RYGBRoux-en-Y
gastric bypass. b Changes in fasting levels of GLP-1 and adipokines. i
Fasting plasma GLP-1 levels. In subjects with persistent N/V, fasting
GLP-1 levels were elevated (P=0.035) compared to that in subjects
without N/V, morbidly obese subjects, obese and overweight subjects
and lean subjects. Data are shown as median and interquartile ranges and
comparisons made by Mann Whitney U test. ii and iii BMI and fasting
systemic leptin levels. Although BMI (ii) were similar between N/Vand
non N/V groups, plasma leptin levels (iii) were significantly lower in N/V
groups compared to non N/V groups (P=0.04). Data in ii are shown as
mean (SD) and in iii as median (interquartile range). iv Fasting plasma
adiponectin levels. Plasma adiponectin was not significantly different
between N/V and non N/V groups. Data are shown as median
(interquartile range) and comparisons made by Mann Whitney U test.
Groups: post-operative nausea and vomiting (N/V) n=10; post-operative
non N/V n=10; morbidly obese (MO) n=7; obese and overweight (OW)
n=6; and lean n=9
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buffered saline with 0.1 % bovine serum albumin). After 4 or
16 h of incubation (37 °C and 5 % CO2) culture media were
collected, and leptin levels were determined.
Statistical Analysis
Results are expressed as mean and standard deviation for
normally distributed data and median and interquartile ranges
for skewed data. Significance was defined as P<0.05.
Results
All subjects were female, non-diabetic, normotensive and
normolipidaemic. The groups were matched for age. BMI
on the day of study varied according to the group (Table 1).
The mean BMI of morbidly obese patients and lean subjects
were 46.3 and 21.3 kg/m2, respectively. The BMI of the post-
operative and the obese/overweight patients was not signifi-
cantly different. Weight loss was not significantly different in
subjects with and without N/V (Fig. 1a) 15 months after
RYGB surgery. Fasting plasmaGLP-1 levels were significant-
ly higher in the subjects with persistent N/V post-RYGB
surgery compared to all other groups (P=0.007, Fig. 1b(i)).
This difference was significant (P=0.03) despite similar BMI
(P=0.86) in the two post-operative groups.
Morbidly obese subjects had the highest systemic leptin
levels. Subjects with post-operative N/V had significantly
lower plasma leptin concentrations compared to that of
asymptomatic post-operative patients. In fact, leptin levels in
these patients were similar to those observed in lean subjects
(Fig. 1b(ii and iii)). However, fasting plasma adiponectin
levels were not significantly different in subjects with post-
operative N/V compared with all other groups (P=0.2
Fig. 1b(iv)). Furthermore, there was no significant difference
in the post-prandial glucose and insulin response in subjects
with and without post-operative N/V (Fig. 2). No significant
differences in the magnitude of the post-prandial GLP-1 re-
sponse were seen in subjects with and without post-operative
N/V.
In vitro experiments showed that leptin secretion from SAT
was significantly suppressed in the presence of GLP-1 after
16 h [GLP-1 treatment: 0 vs. 0.1 nM {2.6 ng/ml (0.4) vs.
1.9 ng/ml (0.4), P=0.06}; 0 vs. 0.5 nM {2.6 ng/ml (0.4) vs.
1.1 ng/ml (0.31), P=0.003}; 0 vs. 1.0 nM {2.6 ng/ml (0.4) vs.
1.0 ng/ml (0.29), P=0.001}]. Treatment with GLP-1 for 4 h
did not produce any significant changes in SAT leptin release.
Discussion
N/V is a common side effect experienced by the majority of
patients undergoing RYGB, but symptoms usually disappear
shortly after the operation [12]. However, approximately 1–
5 % of patients present with difficult to control persistent N/V
despite the absence ofmechanical abnormalities [2].We found
that symptomatic patients have significantly higher basal, but
not post-prandial, GLP-1 levels, suggesting that non-
mechanical chronic N/V symptoms after RYGB surgery
Fig. 2 Glucose and insulin
response to a meal challenge in
subjects with and without nausea
and vomiting post Roux-en-Y
gastric bypass surgery. Following
an 180-kcal meal challenge, the
glucose and insulin responses
were similar in subjects with (i
and ii) and without N/V
symptoms (iii and iv) after Roux-
en-Y gastric bypass surgery. Data
are shown as median and
interquartile ranges and
comparisons made with Mann
Whitney U test
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may be due, at least in part, to chronically elevated GLP-1
levels. Increased GLP-1 concentrations may therefore also
explain similar symptoms seen after other bariatric procedures
such as sleeve gastrectomy [13]. The significant number of
diabetic patients treated with exendin-4 also experience N/V
[6], providing further support for the role of elevated GLP-1
levels on the generation of symptoms.
Exendin-4 induces nausea by penetrating the BBB and
subsequently activating GLP-1R in the medial NTS [5, 4].
Whether GLP-1 induces N/V by direct actions on the NTS or
indirectly through vagal afferent pathway is not known. How-
ever, endogenous GLP-1 has a very short half-life and is
rapidly degraded by DPP-4 enzyme, which makes it unlikely
to cross the BBB.
Despite higher basal GLP-1 levels in symptomatic patients
compared to those without symptoms post-operatively, weight
loss, insulin sensitivity and adiponectin levels were not sig-
nificantly different in both groups. Thus, the beneficial effects
of RYGB on improving insulin sensitivity and weight loss
were not affected by elevated basal GLP-1 levels and the
symptoms of N/V. Contrary to data from the persistent N/V
that accompanies pregnancy [10], systemic leptin levels were
lower in the symptomatic compared to asymptomatic subjects,
despite similar post-operative BMI. Our in vitro study showed
that chronic (16 h), but not acute (4 h), exposure to GLP-1
inhibited leptin secretion from human subcutaneous adipose
tissue. GLP-1 has been shown to inhibit visfatin and exendin-
4 to stimulate adiponectin secretion from 3T3-L1 adipocytes
[14, 15]. The acute administration of synthetic human GLP-1
to obese patients with and without T2DM reduced circulating
interleukin-6 in only those with T2DM, without affecting
levels of leptin, adiponectin or obestatin [16]. Therefore, it
appears that only chronic, but not acute, exposure to elevated
levels of GLP-1, either in vivo or in vitro, leads to inhibition of
leptin.
Leptin stimulates GLP-1 secretion from the hypothalamus
and may be involved in the regulatory mechanisms of GLP-1
production by L cells [17]. As leptin stimulates GLP-1 secre-
tion in a negative feedback mechanism, GLP-1 may directly
inhibit leptin secretion. Inhibition of leptin secretion byGLP-1
was observed in subcutaneous adipose tissue, the major depot
contributing to its systemic levels. That this is a direct effect
on secretion rather than a reflection of differences in fat mass
in patients with and without N/V is substantiated by the fact
that the groups with and without N/V had similar BMI, insulin
sensitivity and adiponectin levels.
The non-mechanical nausea and vomiting symptoms ex-
perienced by some patients was associated with high baseline
levels of GLP-1. We hypothesise that symptoms may be
ameliorated by treatment with GLP-1 inhibitors, but potential
detrimental effects on weight maintenance and insulin sensi-
tivity need to be considered. One of our patients was treated
with octreotide, a somatostatin analogue that inhibits GLP-1
secretion [18], and reported improvement in N/V symptoms,
with concomitant reduction in basal and post-prandial GLP-1
levels. However, octreotide also suppresses other gut hor-
mones, such as PYY, which also decreases appetite and in-
creases weight loss and are increased after RYGB surgery
[18]. Therefore, specific GLP-1 antagonists, such as exendin
9-39, might be more beneficial in improving N/V symptoms,
without interfering with the secretion of other gut peptides that
may potentially affect weight loss and insulin sensitivity
adversely.
This is the first report of a direct effect of GLP-1 on the
secretion of an adipokine, leptin, by human adipose tissue.
The chronic elevation of the gut peptide has an inhibitory
effect on both systemic leptin levels and its secretion from
adipose tissue. Previous reports of decreased leptin levels
early after RYGB, prior to significant reduction in BMI [19],
might be explained by the GLP-1-mediated inhibition of
leptin. The findings in this study suggest that persistent N/V
after RYGB surgery may be mediated by elevated fasting
GLP-1 levels. Further studies are required to determine if
treatment with specific GLP-1 antagonists ameliorates N/V
symptoms without detrimental effects.
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